Drug administration by jet nebulization
1998; Wiley; Volume: 26; Issue: 6 Linguagem: Inglês
10.1002/(sici)1099-0496(199812)26
ISSN8755-6863
AutoresAllan L. Coates, Sharon L. Ho,
Tópico(s)Neonatal Respiratory Health Research
ResumoPediatric PulmonologyVolume 26, Issue 6 p. 412-423 State of the Art Drug administration by jet nebulization Allan L. Coates MD, CM, Corresponding Author Allan L. Coates MD, CM [email protected] Divisions of Respiratory Medicine and Lung Biology Research, Hospital for Sick Children Research Institute, and University of Toronto, Toronto, CanadaDivision of Respiratory Medicine, Hospital for Sick Children, 555 University Ave., Toronto, Ontario M5G 1X8, CanadaSearch for more papers by this authorSharon L. Ho BSc, RRT, Sharon L. Ho BSc, RRT Divisions of Respiratory Medicine and Lung Biology Research, Hospital for Sick Children Research Institute, and University of Toronto, Toronto, CanadaSearch for more papers by this author Allan L. Coates MD, CM, Corresponding Author Allan L. Coates MD, CM [email protected] Divisions of Respiratory Medicine and Lung Biology Research, Hospital for Sick Children Research Institute, and University of Toronto, Toronto, CanadaDivision of Respiratory Medicine, Hospital for Sick Children, 555 University Ave., Toronto, Ontario M5G 1X8, CanadaSearch for more papers by this authorSharon L. Ho BSc, RRT, Sharon L. Ho BSc, RRT Divisions of Respiratory Medicine and Lung Biology Research, Hospital for Sick Children Research Institute, and University of Toronto, Toronto, CanadaSearch for more papers by this author First published: 07 January 1999 https://doi.org/10.1002/(SICI)1099-0496(199812)26:6 3.0.CO;2-OCitations: 24AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Brain JD, Blanchard JD. Mechanisms of particle deposition and clearance. In: F Moren, MB Dolovich, MT Newhouse, SP Newman, editors. Aerosols in medicine: principles, diagnosis and therapy. 2nd ed. Amsterdam, London, New York, and Tokyo: Elsevier; 1993. p 117–156. 2 Edwards DA, Hanes J, Caponetti G, Hrkach J, Ben-Jebria A, Eskew ML, Mintzes J, Deaver D, Lotan N, Langer R. Large porous particles for pulmonary drug delivery. Science 1997; 276: 1868–1871. 3 Chua HL, Collis GG, Newbury AM, Chan K, Bower GD, Sly PD, LeSouëf PN. The influence of age on aerosol deposition in children with cystic fibrosis. Eur Respir J 1994; 7: 2185–2191. 4 Schuh S, Johnson DW, Stephens D, Callahan S, Winders P, Canny GJ. Comparison of albuterol delivery via a metered dose inhaler with spacer versus a nebulizer in children with mild to moderate acute asthma. J Pediatr 1998; submitted. 5 MacNeish CF, Meisner D, Thibert R, Kelemen S, Vadas EB, Coates AL. A comparison of pulmonary availability between Ventolin (Albutero) nebules and Ventolin (Albutero) Respirator Solution. Chest 1997; 111: 204–208. 6 Coates AL, MacNeish CF, Meisner D, Kelemen S, Thibert R, MacDonald J, Vadas EB. The choice of jet nebulizer, nebulizing flow and the addition of ventolin respiratory solution affects to-bramycin aerosols used in cystic fibrosis. Chest 1997; 111: 1206–1212. 7 Maddison J, Dodd M, Webb AK. Nebulized colistin causes chest tightness in adults with cystic fibrosis. Respir Med 1994; 88: 145–147. 8 Dodd M, Abbott J, Maddison J, Moorcroft AJ, Webb AK. Effect of tonicity of nebulized colistin on chest tightness and pulmonary function in adults with cystic fibrosis. Thorax 1997; 52: 656–658. 9 Hinds WC. Particle size statistics. In: Aerosol technology: properties, behaviour, and measurements of airborne particles. New York, Chichester, Brisbane, Toronto, and Singapore: John Wiley and Sons; 1982. p 69–103. 10 Swift DL. Aerosol characterization and generation. In: F Moren, MB Dolovich, MT Newhouse, SP Newman, editors. Aerosol in medicine. 2nd ed. Amsterdam, London, New York, and Tokyo: Elsevier; 1993. p 61–83. 11 Clark AR. The use of laser diffraction for the evaluation of the aerosol clouds generated by medical nebulizers. Int J Pharm 1995; 115: 69–78. 12 Ho SL, Coates AL. The effects of dead volume on the calculation of the actual cost to deliver commonly used medication in cystic fibrosis with four disposable nebulizer. Pediatr Pulmonol 1998; unpublished data. 13 Cipolla DC, Clark AR, Chan H, Gonda I, Shire SJ. Assessment of aerosol delivery systems for recombinant human deoxyribonuclease. S T P Pharma Sci 1994; 4: 50–62. 14 Dennis JH, Hendrick DJ. Design characteristics for drug nebulizers. J Med Eng Technol 1992; 16: 63–68. 15 Schwarz LA, Johnson JL, Black M, Cheng SH, Hogan ME, Waldrep JC. Delivery on DNA-cationic liposome complexes by small-particle aerosol. Hum Gene Ther 1996; 7: 731–741. 16 Eastman SJ, Tousingant JD, Lukason MJ, Murray H, Siegel CS, Constantino P, Harris DJ, Cheng SH, Scheule RK. Optimization of formulations and conditions for aerosol delivery of functional cationic lipid: DNA complexes. Hum Gene Ther 1997; 8: 313–322. 17 Rosenfeld M, Emerson J, Astley S, Joy P, Williams-Warren J, Standaert TA, Yim DL, Crist D, Thykkuttatihil M, Torrence M, Fitz Simmons S, Ramsey B. Home nebulizer use among patients with cystic fibrosis. J Pediatr 1998; 132: 125–131. 18 Standaert TA, Morlin G, Weber A, Pepe M, Ramsey BW. The preformace of disposable jet nebulizers after repeated use. Pediatr Pulmonol 1995; 12: 256 [abstract]. 19 Coates AL, MacNeish CF, Lands LC, Meisner D, Kelemen S, Vadas EB. A comparison of the availability of tobramycin for inhalation from vented versus unvented nebulizers. Chest 1998; 113: 951–956. 20 Newnham DM, Lipworth BJ. Nebuliser performance, pharmokinetics, airways and systemic effects of salbutamol given via a novel nebuliser delivery system ("Ventstream"). Thorax 1994; 49: 762–770. 21 Kwong E, MacNeish CF, Meisner D, Kelemen S, Vadas EB, Coates AL. The use of osmometry as a means of determining changes in drug concentration during jet nebulization. J Aerosol Med 1998; 11: 89–100. 22 O'Callaghan C, Clarke AR, Milner AD. Inaccurate calculation of drug output from nebulisers. Eur J Pediatr 1989; 148: 473–474. 23 Coates AL, MacNeish CF, Lands LC, Smountas A, Meisner D, Kelemen S, Vadas EB. Factors influencing the rate of drug output during the course of wet nebulization. J Aerosol Med 1998; 11: 101–111. 24 Weber A, Morlin G, Cohen M, Williams-Warren J, Ramsey BW, Smith AL. Effect of nebulizer type and antibiotic concentration on device performance. Pediatr Pulmonol 1997; 23: 249–260. 25 Loffert DT, Ikle D, Nelson HS. A comparison of commercial jet nebulizers. Chest 1994; 106: 1788–1792. 26 Hollie MC, Malone RA, Skufea RM, Nelson HS. Extreme variability in aerosol output of the De Vilbiss 646 neublizer. Chest 1991; 100: 1339–1344. 27 Clay MM, Pavia D, Newman SP, Lennard-Jones T, Clarke SW. Assessment of jet nebulisers for lung aerosol therapy. Lancet 1983; ii: 592–594. 28 Newman SP, Clarke SW. Therapeutic aerosols 1-Physical and practical considerations. Thorax 1983; 38: 881–886. 29 Dennis JH, Stenton SC, Beach JR, Avery AJ, Walters EH, Hendrick DJ. Jet and ultrasonic nebuliser output: use of a new method for direct measurement of aerosol output. Thorax 1990; 45: 728–732. 30 Schöni MH, Kraemer R. Osmolarity changes in nebulizer solutions. Eur Respir J 1989; 2: 887–892. 31 Cockcroft DW, Hurst TS, Gore BP. Importance of evaporative water losses during standardized nebulized inhalation provocation tests. Chest 1989; 96: 505–508. 32 Langford SA, Allen MB. Salbutamol output from two jet nebulizers. Respir Med 1993; 87: 99–103. 33 Wood JA, Wilson RSE, Bray C. Changes in salbutamol concentration in the reservoir solution of a jet nebulizer. Br J Dis Chest 1986; 80: 164–169. 34 Everard ML, Clark AR, Milner AD. Drug delivery from jet nebulizers. Arch Dis Child 1992; 67: 586–591. 35 Muers MF. The rational use of nebulizers in clinical practice. Eur Respir Rev 1997; 7: 189–197. 36 Hess D, Fisher D, Williams P, Pooler S, Kacmarek RM. Medication nebulizer performance: effects of diluent volume, nebulizer flow and nebulizer brand. Chest 1996; 110: 498–505. 37 Smith EC, Denyer J, Kendrick AH. Comparison of twenty-three nebulizer/compressor combinations for domiciliary use. Eur Respir J 1995; 8: 1214–1221. 38 Morrow PE. Aerosol characterization and deposition. Am Rev Respir Dis [Suppl] 1974; 110: 88–99. 39 Nikander K. Some technical, physiochemical and physiological aspects of nebulizer therapy. Eur Respir Rev 1997; 7: 168–172. 40 Ramsey BW, Dorkin HL, Eisenberg JD, Gibson RL, Harwood IR, Kravitz RM, Schidlow DV, Wilmott RW, Astley SJ, McBurnie MA, Wentz K, Smith AL. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med 1993; 328: 1740–1746. 41 Hodson ME, Penketh ARL, Batten JC. Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in pateints with cystic fibrosis. Lancet 1981; ii: 1137–1139. 42 MacLusky IB, Levison H, Gold R, McLaughlin FJ. Inhaled antibiotics in cystic fibrosis: is there a clinical effect? J Pediatr 1986; 108: 861–865. 43 Stead RJ, Hodson ME, Batten JC. Inhaled ceftazadime compared with gentamicin and carbenicillin in older patients with cystic fibrosis infected with Pseudomonas aeruginosa. Br J Dis Chest 1987; 81: 272–279. 44 Schaad UB, Wedgwood-Krucko J, Suter S, Kraemer R. Efficacy of inhaled amikacin as adjunct to intravenous combination therapy (ceftazidime and amikacin) in cystic fibrosis. J Pediatr 1987; 111: 599–605. 45 MacLusky IB, Gold R, Corey ML, Levison H. Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatr Pulmonol 1989; 7: 42–48. 46 Davies J, Trindade M-T, Wallis C, Rosenthal M, Crawford O, Bush A. Retrospective review of the effects of rhDNase in children with cystic fibrosis. Pediatr Pulmonol 1997; 23: 243–248. 47 Wilmott RW, Amin RS, Colin AA, DeVault A, Dozor AJ, Eigen H, Johnson C, Lester LA, McCoy K, McKean LP, Moss R, Nash ML, Jue CP, Regelmann W, Stokes DC, Fuchs HJ. Aerosolized recombinant human DNase in hospitalized cystic fibrosis patients with acute pulmonary exacerbations. Am J Respir Crit Care Med 1996; 153: 1914–1917. 48 Hubbard RC, McElvaney NG, Birrer P, Shak S, Robinson WW, Jolly C, Wu M, Chernick MS, Crystal RG. A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis. N Engl J Med 1992; 326: 812–815. 49 Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, Rosenstein BJ, Smith AL, Wohl MEB. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994; 331: 637–642. 50 McCoy K, Hamilton S, Johnson C, For the Pulmozyme Study Group. Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Chest 1996; 110: 889–895. 51 Ramsey BW, Astley SJ, Aitken ML, Burke W, Colin AA, Dorkin HL, Eisenberg JD, Gibson RL, Harwood IR, Schidlow DV, Wilmott RW, Wohl ME, Meyerson LJ, Shak S, Fuchs H, Smith AL. Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. Am Rev Respir Dis 1993; 148: 145–151. 52 Ramsey BW, Dorkin HL. Consensus conference: Practical implications of Pulmozyme. Pediatr Pulmonol 1994; 17: 404–408. 53 Kun P, Landau LI, Phelan PD. Nebulized gentamycin in children and adolescents with cystic fibrosis. Aust Paediatr J 1984; 20: 43–45. 54 Health Care and Environment Sector Board. Respiratory therapy equipment, part 3: specification for gas-powered nebulizers for the delivery of drugs. BSi Standards BS 7711 1994; 3: 1–9. 55 O'Callaghan C, Barry PW. The science of nebulised drug delivery. Thorax 1997; 52: 31–44. 56 Hung JCC, Hambelton G, Super M. Jet nebulising systems for recombinant human DNase. Arch Dis Child 1994; 71: 558–559. 57 Dennis JH. Drug nebuliser design and performance: breath enhanced jet vs. constant output jet vs. ultrasonic. J Aerosol Med 1995; 8: 277–280. Citing Literature Volume26, Issue6December 1998Pages 412-423 ReferencesRelatedInformation
Referência(s)